Navigation Links
Lung cancer cells activate inflammation to induce metastasis
Date:12/31/2008

A research team from the University of California, San Diego School of Medicine has identified a protein produced by cancerous lung epithelial cells that enhances metastasis by stimulating the activity of inflammatory cells. Their findings, to be published in the January 1 issue of the journal Nature, explain how advanced cancer cells usurp components of the host innate immune system to generate an inflammatory microenvironment hospitable for the metastatic spread of lung cancer. The discovery could lead to a therapy to limit metastasis of this most common lethal form of cancer.

The scientists headed by Michael Karin, Ph.D., UC San Diego Distinguished Professor of Pharmacology and Pathology, who has been investigating the effects of inflammation on cancer development and progression used a straightforward biochemical approach to identify proteins produced by metastatic cancer cells that are responsible for generation of an inflammatory microenvironment that supports the growth of metastases. Focusing on macrophages, white blood cells that are key players in the immune response to foreign invaders as well as in cancer growth and progression, they screened for factors produced by metastatic cancer cells in mice that could stimulate the activity of this inflammatory cell type.

Among the mouse cell lines screened, a highly metastatic cell line called Lewis lung carcinoma (LLC) showed particularly potent activation of macrophages. Furthermore, macrophage activation was mediated by a secreted protein. Biochemical purification of proteins secreted by LLC cells resulted in identification of an extracellular matrix protein called versican as the major macrophage activator and metastasis enhancing factor. Versican is also found in very low amounts in normal human lung epithelial cells, but is upregulated in human lung cancer, where a very large amount of this protein is found, especially in aggressive tumors.

The scientists found that versican strongly enhances LLC metastatic growth by activating receptors that lead to production of cytokines signaling proteins that regulate the immune system. One of these receptors, TLR2, and a cytokine, TNFα, were found to be required for LLC metastasis. However, the normal function of TLR2 and TNF is in host defense-innate immunity to microbial infections. According to Karin, these findings are relevant, not just to the mouse model, but also to human lung cancer the most common cause of cancer-related deaths worldwide. The major cause of lung cancer is tobacco smoking.

"By usurping these elements of the host immune system, versican helps generate an inflammatory environment that spurs the growth and spread of metastatic cancer," said Karin. "If we can find a way to block the production of versican or its binding to TLR2, therapeutic intervention could be used to limit metastasis of lung cancer."


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Why prostate cancer patients fail hormone deprivation therapy
2. Few DNA repair genes maintain association with cancer in field synopsis
3. High Insulin May Boost Odds of Breast Cancer
4. Vitamins Fail to Prevent Cancer: Study
5. Errors involving medications common in outpatient cancer treatment
6. Young blood fights cancer
7. Food Phosphates Might Spur Lung Cancer
8. Minimizing obesitys impact on ovarian cancer survival
9. RCOG.com and ProstRcision.com Increase Online Presence for Cancer Information
10. Lung Cancer: Still the Biggest Cancer Killer, by Far
11. Cancer drug effectively treats transplant rejections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... , ... May 01, 2016 , ... Serenity Recovery, a ... rehabilitation, has produced a new video that focuses on one of the more popular ... sessions and clips from interviews with a participating patients and the Yoga class instructor, ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... RANKED Health , a program to critically evaluate and rank health-focused applications and ... program is to provide independent, unbiased and accurate information to help accelerate patient ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... the use of the HyProCure sinus tarsi implant. ( http://www.cbc.ca/news/canada/ottawa/banned-quebec-dentist-pierre-dupont-working-as-chiropodist-in-ottawa-1.3515494 ) ... a minimally invasive procedure performed, when indicated, to correct the partial displacement ...
(Date:4/29/2016)... ... April 30, 2016 , ... World Patent Marketing , ... Springboard, an automotive invention that improves the storage features of a pick up ... says Scott Cooper, CEO and Creative Director of World Patent Marketing. "Over the ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... Two Ten Footwear Foundation, the national charitable foundation serving the footwear industry, has ... 8,000 volunteers representing more than 130 companies across 23 states during the months ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology ... appointment of Dr. Alfredo Zurlo as Chief ... with many years clinical experience and a proven track ... role was at Mologen AG where he was Chief ... Dr. Zurlo held various positions at F Hoffmann La ...
(Date:4/28/2016)... NEW YORK , April 28, 2016 /PRNewswire/ ... will notably complement the company,s valve repair and ... the move also places Abbott more firmly into ... one of the fastest growing device areas, with ... to its recent report,  Advanced Remote Patient ...
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
Breaking Medicine Technology: